Royalty Report: Drugs, Disease, Therapeutic – Collection: 237236


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Disease
  • Therapeutic
  • Vaccine

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 237236

License Grant
Licensor grants to the Licensee of Denmark a non-exclusive, non-transferable, worldwide, royalty-bearing license, with the right to grant sublicenses, under the Licensed Technology to make, have made, sell, have sold and import Products in the Field during the Term. For avoidance of doubt, Licensee shall only have the right under the license granted to use PADRE® as part of a Product.

Licensee shall have the right to grant sublicenses.

License Property
Licensed Technology shall mean, to the extent necessary or useful for research, development, manufacture, use, sale or import of Products in the Field, all Patent Rights and Know-How, including all PADRE® Improvements.

PADRE® shall mean a peptide capable of binding antigen binding sites on major histocompatibility complex (MHC) molecules encoded by substantially all alleles of a DR locus, including, without limitation, a composition comprising a peptide recited in the claims of United States Patent Application Serial No. 08/121,101 and any patent applications, U.S., international and foreign, that derive priority from such patent application, such as continuing applications and any patents issuing therefrom. Such peptides are also referred to as pan DR binding peptides and include, without limitation, AKXV AA WTLKAAA,using the single letter designation for amino acids, wherein X is cyclohexylalanine or phenylalanine, and other peptides claimed and/or disclosed in the patent applications.

Product shall mean any product that contains, is comprised of or uses PADRE® in combination or association with any AutoVac™ Molecule.

Field of Use
Field shall mean the prevention and/or treatment of diseases or disorders in humans.

The license is to use PADRE technology for use in connection with their AutoVacâ„¢ technology for controlling autoimmune diseases.
The PADRE technology consists of a family of small (13 amino acid), synthetic proprietary molecules that are potent immunostimulants, meaning that they stimulate the immune response.

IPSCIO Record ID: 212650

License Grant
The Licensor grants to Licensee a non-exclusive, royalty-bearing license, with the right to grant sublicenses, under the Patents to Exploit the Licensed Product in the Field in the Territory and to Manufacture or have Manufactured the Compound in connection with such Exploitation of the Licensed Product.  Field shall mean the use of the Licensed Product for the prevention of infection by Hepatitis B Virus in humans.  Delivery Method for the Licensed Product shall mean intramuscular or subcutaneous delivery.
License Property
The Licensor is the owner or licensee of certain rights in proprietary technologies involving immunomodulatory oligonucleotides.

“Licensed Product” shall mean a prophylactic vaccine containing the Compound co-formulated with the Antigen for delivery by the Delivery Method. No Licensed Product(s) may be developed for the prevention, treatment or control of any cancer nor may any clinical trial be conducted with clinical endpoints of prevention, treatment or control of any cancer.

Patents Claiming Priority to Patent Application Serial No. 08/276,358

Field of Use
“Field” shall mean the use of the Licensed Product for the prevention of infection by Hepatitis B Virus in humans. The Field specifically excludes any product for the prevention of disease, indications or disorders other than Hepatitis B Virus in humans and any product for the treatment of any disease, indications or disorders.

IPSCIO Record ID: 277105

License Grant
For outside the licensed field, Licensor grants a worldwide, non-exclusive, and sublicenseable right and license to practice Licensors rights in Joint Collaboration Patent Rights to make, have made, import, promote, market, distribute or sell Licensee Products outside the Licensed Field.

This agreement contains both exclusive and non-exclusive grants between the parties.

License Property
The Patent Rights and Know-How are pertaining to the PADRE® Technology.

Licensed Product shall mean a therapeutic or prophylactic vaccine the manufacture. use or sale of which, but for any license granted to Licensee herein, would infringe a Valid Claim of one or more Licensor Patent Rights or one or more Collaboration Patent Rights, or was developed or manufactured using Licensor Know-How.

PADRE® Technology shall mean a family of immunostimulatory molecules which when combined with cytotoxic T cell epitopes increase the magnitude and duration of the immune response.

Field of Use
Licensed Field shall mean the research, development and commercialization of Licensed Products for treating or preventing diseases associated with the following viruses HPV. HBV and HCV.  HBV shall mean Hepatitis B Virus.  HCV shall mean Hepatitis C Virus.  HPV shall mean Human Papilloma Virus.  First HPV Indication shall mean treatment or prevention of cervical dysplasias and neoplasia.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.